Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
LEUKINE 250MCG VIL INJ (5PKG) is a federal award for Aspr/Orm-Sns held by Partner Therapeutics, Inc. Estimated value $133.5M ($133.5M obligated). Current period of performance ends Mar 29, 2027 (potential Sep 29, 2027). Last award drew 1 bidder. Place of performance: LEXINGTON, MA. Related solicitation 75A50323Q00021.
Recompete timing
PublicCurrent PoP ends Mar 29, 2027 (221 days remaining). Agencies typically plan 12–18 months ahead — at 7.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordPartner Therapeutics, Inc — $147.4M obligated across 9 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50323F80027?
75A50323F80027 (Leukine 250mcg VIL INJ (5pkg) is a Aspr/Orm-Sns award with an estimated value of $133.5M, currently held by Partner Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50323F80027?
Aspr/Orm-Sns awarded 75A50323F80027 to Partner Therapeutics, Inc.
Who is the incumbent on 75A50323F80027?
Partner Therapeutics, Inc is the incumbent with $147.4M across 9 related awards in SCOUT’s public footprint. The current period of performance ends Mar 29, 2027.
When does Partner Therapeutics, Inc’s 75A50323F80027 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.